Home › Graves Ophthalmopathy › NCT06275373
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * only DOD beneficiaries * adult patients 18 years of age or older * adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease Exclusion Criteria: * Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation * patients with a history of uncontrolled diabetes mellitus * patients with a history/diagnosis of uncontrolled inflammatory bowel disease * patients under age 18 years * patients who are pregnant or trying to become pregnant.
About the study
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).
What is being tested
- Teprotumumab Injection [Tepezza] (drug)
Sponsor: Walter Reed National Military Medical Center · Participants: 100 · Started: May 12, 2021
Contact the study team
- THANH D HOANG, DO · Phone: 3012955165
- Iris Morris, PhD · Phone: 3013194599
Official record on ClinicalTrials.gov — NCT06275373
Locations in the U.S.
| Maryland | Walter Reed National Military Medical Center, Bethesda |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.